source · application/json
source_fb63a37ad1064e06
sha256 bf155e826fdcb2eeff5649d21604153ac98f9084d6e3f316a81c388df042ad25
by researka:v2 · 2026-07-14 17:35:13.538536+04:00
{"publication_id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "traces": [{"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "Across retrieved source-level receipts for empagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "claim_id": "claim_1"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "Finding: SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.", "claim_id": "claim_2"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |", "claim_id": "claim_3"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "| outcome-specific | Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose... | directionally favorable | patients with type 2 diabetes mellitus | - | SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA |", "claim_id": "claim_4"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "| outcome-specific | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3... | directionally favorable | patients with T2DM and increased cardiovascular... | - | relative risk reductions in major adverse cardiac events (14%) |", "claim_id": "claim_5"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "This receipt-backed scoping note has one bounded signal: empagliflozin shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2016-2023). Evidence role grouping: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. The source facts cover 5 population/setting context(s) and 2 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim.", "claim_id": "claim_6"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "claim_id": "claim_7"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "directionally favorable: Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment — SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.", "claim_id": "claim_8"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "directionally favorable: Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials — relative risk reductions in major adverse cardiac events (14%)", "claim_id": "claim_9"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "Evidence role summary: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0.", "claim_id": "claim_10"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "Specific moderators in this bundle are population/indication (CKD patients based on eGFR slopes; patients with T2DM and increased cardiovascular risk; patients with T2DM and/or HF; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and established cardiovascular disease), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.", "claim_id": "claim_11"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "Population/settings are separated as receipt context: CKD patients based on eGFR slopes, patients with T2DM and increased cardiovascular risk, patients with T2DM and/or HF, patients with type 2 diabetes mellitus, and patients with type 2 diabetes mellitus and established cardiovascular disease. The selected receipts group because each carries a fact-level extraction for empagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "claim_id": "claim_12"}, {"candidate_sources": [{"directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and/or HF", "source_id": "source_1", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/eurjpc/zwab173"}, {"directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus", "source_id": "source_2", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/jaha.119.015716"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "source_id": "source_3", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1161/circulationaha.116.021887"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "population": "patients with T2DM and increased cardiovascular risk", "source_id": "source_4", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "support_kind": "candidate_source_row", "url": "https://doi.org/10.2174/1573399812666160613113556"}, {"directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "population": "CKD patients based on eGFR slopes", "source_id": "source_5", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "support_kind": "candidate_source_row", "url": "https://doi.org/10.1093/ckj/sfad082"}], "claim": "The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "claim_id": "claim_13"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780",
"researka_submission_id": "744bb98c-afc3-4bed-b1cf-5fab7cc791a2",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/ba51abd9-ce97-48b3-b9e2-eb5a53bbd780/sidecars/citation_traces.json"
}